Discover opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Jan 24, 2022 to Jan 24, 2022
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| Office of Acquisition Managementt Policy | Detect, Inc. | Jan 24, 2022 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES PRECLINICAL, REGULATORY, AND MANUFACTURING DEVELOPMENT ACTIVITIES.
Effective Date
Mar 18, 2022
Expires
Effective: Mar 18, 2022
THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES PRECLINICAL, REGULATORY, AND MANUFACTURING DEVELOPMENT ACTIVITIES.
ActiveADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ
Effective Date
Sep 29, 2023
Expires
Effective: Sep 29, 2023
ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ
ActiveADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR
Effective Date
Sep 30, 2024
Expires
Effective: Sep 30, 2024
ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR
ActiveGEN1E - THIS CONTRACT WILL PROVIDE SUPPORT TO GEN1E LIFESCIENCES INC. (GEN1E), A US COMPANY, FOR THE ADVANCEMENT OF PATIENT STRATIFICATION AND ENDOTYPING APPROACHES AS IT DEVELOPS GEN-1124, A NOVEL TREATMENT FOR ACUTE RESPIRATORY DISTRESS SYNDROME (A
Effective Date
Sep 22, 2023
Expires
Effective: Sep 22, 2023
GEN1E - THIS CONTRACT WILL PROVIDE SUPPORT TO GEN1E LIFESCIENCES INC. (GEN1E), A US COMPANY, FOR THE ADVANCEMENT OF PATIENT STRATIFICATION AND ENDOTYPING APPROACHES AS IT DEVELOPS GEN-1124, A NOVEL TREATMENT FOR ACUTE RESPIRATORY DISTRESS SYNDROME (A
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis